Sermorelin Testing
MW: 3357.88 g/molHalf-life: ~10–20 minutesStatus: Previously FDA-approved
Synthetic GHRH (1-29) analog. Short half-life.
Mechanism of action
GHRH(1-29), the minimum N-terminal fragment retaining full agonist activity at the GHRH receptor. Stimulates pulsatile GH release.
Research areas
- ●Pediatric GH deficiency (historical FDA indication)
- ●Age-related GH decline research
- ●Body composition
What we test on Sermorelin
RP-HPLC with shallow gradient to resolve deamidation isomers; intact mass and MS/MS confirmation; endotoxin for injectables.
Standard GH Secretagogues Panel
- ✓RP-HPLC purity
- ✓ESI-MS identity
- ✓Amino acid analysis
- ✓Residual solvents (GC-MS)
Common impurities & failure modes
- Asn8 deamidation
Primary stability indicator; produces Asp/iso-Asp variants visible as 1–3 minute earlier-eluting peaks.
- Met27 oxidation
+16 Da shift.
- Sequence truncations
Standard SPPS failures, particularly the C-terminal Arg-Ser-Arg stretch.
Regulatory status
Previously FDA-approved (Geref, Geref Diagnostic) — withdrawn for commercial reasons, not safety.
Related GH Secretagogues peptides
CJC-1295 (DAC)
3647.28 g/mol
GHRH analog with Drug Affinity Complex for extended half-life (~8 days).
CJC-1295 (no DAC) / Modified GRF 1-29
3367.93 g/mol
GHRH analog without DAC, shorter half-life than CJC-1295 with DAC.
GHRP-2
817.97 g/mol
Synthetic hexapeptide stimulator of GH release.
GHRP-6
872.97 g/mol
Hexapeptide stimulating GH secretion via the ghrelin receptor.
Hexarelin
887.04 g/mol
Potent hexapeptide GH secretagogue; also studied for cardiac effects.
Ibutamoren (MK-677)
528.66 g/mol
Orally active non-peptide GH secretagogue / ghrelin agonist.